Organocatalysis in total synthesis by Marqués-López, Eugenia & Herrera, Raquel P.
1 
 
XII. Asymmetric Organocatalysis in Total Synthesis 
Eugenia Marqués-López*,1 and Raquel P. Herrera*,1,2 
1 Laboratorio de Síntesis Asimétrica, Departamento de Química Orgánica.  
Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza.  
E-50009 Zaragoza, Spain. Fax: +34 976762075.  
2 ARAID, Fundación Aragón I+D, E-50004 Zaragoza, Spain. 
mmaamarq@unizar.es and raquelph@unizar.es 
 
XII.1 Introduction 
There is no doubt about the importance of natural products in chemistry, biology, and medicine, 
consequently their obtainment has always been a theme of interest for chemists. This was 
traditionally centered in their direct extraction from natural sources, and later the value of 
natural product synthesis has become questionless. Usually these compounds present 
stereogenic carbon centers and therefore, their syntheses must involve ways of getting chirality. 
Chiral pool and resolution of racemates represented the two principal strategies until the birth of 
asymmetric catalysis [1], which has revolutionized the chemical synthesis. In this context, 
asymmetric organocatalysis [2] appeared in the first decade of 21st century as a promising 
powerful tool, complementing metal and enzymatic catalysis. Since seminal works [3], this field 
has exponentially grown due to its main advantage: simplicity. And although the synthesis of 
complex molecules is still an active challenge in organocatalysis, there are already a high 
number of those syntheses where organocatalyzed reactions play a crucial role, showing its 
efficiency with elegance. In this recapitulation we will describe several selected examples 
published in the most recent years [4]. Moreover, this chapter is divided into different sections 
according to the most important modes of activation such as enamine and iminium catalysis, 
Brønsted acid and hydrogen bond catalysis, cinchona alkaloid catalysis, and phase transfer 
catalysis. 
 
XII.2. Aminocatalysis in Natural Product Synthesis 
Within organocatalysis, aminocatalysis has represented a key approach in a high variety of 
fundamental transformations [5]. Since the pioneering works reported contemporaneously by 
List [3a] and MacMillan [3b] in 2000, numerous have been the outcomes achieved in this 
appealing area. In the last twelve years many research groups have used secondary and, more 
recently, primary chiral amines which have become privileged structures as organocatalysts (Fig 
XII.1).  
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Figure XII.1 Chiral amines used as organocatalysts in natural product synthesis.  
 
XII.2.1 Enamine Catalysis 
The condensation reaction between an amine and an enolizable carbonyl compounds rapidly 
affords reactive enamines as nucleophilic intermediates, which have the capacity to react with 
an extensive range of electrophiles rendering the corresponding α-functionalization of those 
carbonyl compounds [6]. Since the pioneering work reported by List et al.[3a], in the last 
decade this mode of activation has witnessed an explosive growth in the field of 
organocatalysis. It is easy to find in the literature, many examples of application in total 
synthesis of this catalysis through different reactions (Fig XII.2). One of the most extensively 
explored has been aldol reaction, key step in the syntheses of callipeltoside C [7], 
convolutamydine A, B, E [8], (+)-przewalskin B [9], ()-salinosporamide A [10], (+)-
spongistatin 1 [11], (S)-()-3-butylphthalide [12], and ()-anominine [13] among many other 
examples. The Mannich reaction, a classical method for the creation of new C-C bonds, can be 
found in the synthesis of natural products, such as (2S,3R,4S)-4-hidroxyisoleucine [14]. 
Furthermore,α-heterofuntionalization of carbonyl compounds via enamine activation has also 
been applied in the synthesis of natural products. Among other examples, α-oxidation is the 
most frequent one: 7,8-O-isopropylidene iriomoteolide-3a [15], (+)-neosymbioimine [16], (+)- 
and ()-disparlure [17], ()-(5R,6S)-6-acetoxy-5-hexadecanolide [18], and Hagen’s gland 
lactones [19]; followed by α-amination: chloptosin [20], (S)-AIDA [21], and Licopodium 
alkaloids [22]. Sometimes α-heterofuntionalization of carbonyl compounds is necessary to form 
a temporal reactive intermediate, as is the case of α-selenylation: (+)-symbioramide [23], and α-
chlorination: ripostatin B [24]. Moreover, organocatalytic Michael addition is other main C-C 
bond-forming strategy widely used in natural product synthesis. Illustrative examples are the 
syntheses of (+)-polyanthellin A [25], (+)-simplactone B [26], biyouyanagin A [27], ()-
oseltamivir [28,29], and ABT-341 [29,30] (Fig XII.2). 
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Figure XII.2 α-Funtionalization of carbonyl compounds via enamine catalysis applied in total 
synthesis. 
 
As an application of this enamine activation we describe the organocatalytic step in the 
construction of ()-bitungolide F (2) skeleton recently published by Cossy and co-workers 
(Scheme XII.1) [31]. This natural product is a polyketide isolated by Tanaka et al. [32] from the 
Indonesian sponge Theonella cf. swinhoei that exhibits cytotoxic effects against 3Y1 rat normal 
fibroblast cells and inhibition toward VH1-related (VHR) dual-specificity phosphatase. The 
total synthesis of 2 starts with a previously reported enantioselective organocatalyzed Michael 
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addition [33] providing enantioenriched aldehyde 1, key intermediate in the synthetic route. 
After eight more additional steps the target molecule 2 is obtained in 11% overall yield.  
 
Scheme XII.1 Synthesis of ()-bitungolide F via an enantioselective organocatalyzed Michael 
addition. 
 
A Michael addition procedure is also the organocatalytic step in the preparation of alkaloids 
dihydrocorynantheol [34,35,36], and protoemetinol [34,36] developed by Ma and co-workers 
(Scheme XII.2). The authors envisioned that intermediate 3 could be further transformed into 
different active alkaloids connecting it with a tryptamine, as the main core of final products. 
 
Scheme XII.2 Syntheses of tryptamine derived alkaloids via an enantioselective 
organocatalyzed Michael addition. 
 
XII.2.2 Dienamine Catalysis 
A less explored mode of activation within aminocatalysis is the so-called dienamine catalysis 
[37]. In this case is an α,β-unsaturated carbonyl compound with a proton in γ position suitable 
of deprotonation that after condensation with a chiral amine provides a reactive nucleophile, but 
now two activated positions are available, being possible both α- and γ-funtionalization of the 
substrate. Additionally, this vinylogous enamine can also act as an electron-rich diene. The 
work published in this area is very scarce to date, and only few examples of its application in 
total synthesis came out in the last years: (+)-palitantin [38], α-tocopherol [39], pungent 
constituent of black cardamom [40], and (R)-rotundial [41] (Fig XII.3). 
 
Figure XII.3 Natural products synthesized via dienamine catalysis. 
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XII.2.3 Iminium Catalysis 
Aminocatalysis has been also successfully applied for the activation of ,-unsaturated 
carbonyl compounds in order to conveniently activate the β-position through a reactive iminium 
ion, a more electrophile specie that the corresponding conjugated system [42]. The electron-
deficient iminium intermediate can be further trapped by incoming electron-rich nucleophiles 
allowing the synthesis of final adducts with excellent levels of enantioselectivities. As well as 
enamine catalysis, iminium catalysis has been widely applied in natural product synthesis. Some 
representative applications of those syntheses employing this LUMO-lowering iminium 
catalysis as one of the key steps, are (+)-ricciocarpin A [43], (+)-fawcettimine [44], (S)-warfarin 
[45], (S)-rolipram [46], dysideaproline [47], INCB018424 [48], iriomoteolide 1b [49], 
psymberin [50], (+)-minfiensine [51], and diazonamide A [52] (Fig XII.4). 
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Figure XII.4 β-Funtionalization of carbonyl compounds via iminium catalysis applied in total 
synthesis. 
 
MacMillan’s group has worked intensively in the field of iminium catalysis, establishing a 
broad scope of applicability using this kind of activation and contributing actively to the 
development of this area. An elegant example is the three-step total synthesis of (+)-frondosin B 
in 50% overall yield [53], a member of a marine sesquiterpene family that exhibit significant 
properties in several therapeutic areas [54] (Scheme XII.3). 
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Scheme XII.3 Total synthesis of (+)-frondosin B via iminium organocatalyzed FriedelCrafts 
reaction. 
 
The key step of this synthetic route is an iminium organocatalyzed FriedelCrafts reaction of an 
in situ generated activated boronate 4 intermediate and crotonaldehyde (5), forming a non-
traditional FriedelCrafts adduct 6, result of an unexplored regioselectivity (C-2 vs C-3). 
Additionally, the feasible structural variations on the starting heteroaryl trifluoroborate salt 
could allow straightforward access to a variety of natural product analogues.  
 
XII.2.4 Organocascade Catalysis: Combinations of Enamine and Iminium Catalysis[55] 
In the last years, multicomponent [56] and domino [57] reactions have attracted the attention of 
a wide number of research groups due to the growing interest in atom economy and sustainable 
chemistry by the scientific community. Attractive achievements have been recently 
accomplished in the field of organocatalysis, being applied in the synthesis of important targets. 
Some extraordinary examples have been presented by MacMillan and co-workers. One is the 
synthesis of (–)-aromadendranediol via a Mukaiyama-Michael-aldol condensation, through a 
triple-catalysis-cycle-specific mechanism involving cross-metathesis, iminium and enamine 
catalysis [58]. And others more recent are the total syntheses of six well-known alkaloids 
(strychnine, aspidospermidine, vincadifformine, akuammicine, kopsanone and kopsinine) based 
on the combination of collective synthesis of natural products and organocascade catalysis [59]. 
Additional remarkable straightforward applications of organocascade catalysis have been 
published by Hong and co-workers. For instance, the first asymmetric total synthesis of (+)-
conicol accomplished through an organocatalytic domino process oxa-Michael-Michael-
Michael-aldol condensation, in a one-pot two-step reaction [60] is depicted in Scheme XII.4. 
Other interesting example is the synthesis of (+)-galbulin via an organocatalytic domino 
Michael–Michael–aldol condensation schematically represented in Scheme XII.4 [61]. 
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Scheme XII.4 Total syntheses of (+)-conicol and (+)-galbulin via cascade organocatalytic 
reaction. 
 
XII.3 Hydrogen Bond Catalysis in Total Synthesis 
Catalysts acting by hydrogen bond interactions have significantly contributed to the progress of 
this area [62]. Among the great number of chiral acid catalysts recently developed and 
successfully applied as organocatalysts, chiral phosphoric acids and chiral (thio)urea have 
become two pivotal research areas in organocatalysis. 
 
XII.3.1 Phosphoric Acids 
Since pioneering works reported in 2004 by Terada[63] and Akiyama [64], chiral phosphoric 
acids have rapidly emerged as a new potent class of Brønsted acid catalysts with remarkable 
synthetic power owing to its continuous application in the development of new organocatalytic 
methodologies and resulting in a significant expansion of this field [65] (Fig XII.5). Proof of 
this substantial progress is the employment of such privileged class of Brønsted acids in the 
total syntheses of significant compounds as, for instance: ()-arboricine A [66], (S)-anabasine 
[67], monastrol [68], ()-zampanolide [69], (+)-galipinine [70,71], (+)-cuspareine [70], ()-
angusturine [70,72], and torcetrapib [73] (Fig XII.6). 
 
Figure XII.5 Chiral phosphoric acid derivatives utilized as organocatalysts. 
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Figure XII.6 Brønsted acid catalyzed remarkable natural product syntheses. 
 
List and co-workers published a practical and useful approach to chiral aminals 7 starting from 
aldehydes and employing chiral phosphoric acids as suitable catalysts. The authors applied this 
novel procedure in the straightforward synthesis of several benzo(thia)diazines pharmaceuticals, 
including (S)-aquamox, (R)-thiabutazide, (R)-penflutizide, (R)-bendroflumethiazide, and (R)-
cyclopenthiazide with excellent enantioselectivities in one reaction step (Scheme XII.5) [74].  
 
Scheme XII.5 Brønsted acid catalyzed synthesis of pharmaceutically relevant compounds. 
 
More recently, a Brønsted acid organocatalyzed nucleophilic substitution reaction of 3-
hydroxindoles 8 with ene-carbamates 9 was successfully developed by Gong’s group for its 
application in the first catalytic enantioselective synthesis of (+)-folicanthine [75], member of 
the large cyclotryptamine alkaloid family which exhibit fascinating biological and 
pharmaceutical activities [76]. The 3,3’-disustituted oxindole intermediate 10 with a chiral 
quaternary stereogenic center is the key chiral building block in this synthetic route (Scheme 
XII.6). 
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Scheme XII.6 Total synthesis of (+)-folicanthine. 
 
XII.3.2 (Thio)urea Organocatalyzed Processes 
A different class of catalysts acting by hydrogen bond interactions covers the large group of 
(thio)urea derivatives (Fig XII.7). Although the application of this family of catalysts seems to 
be limited in comparison with Lewis acids due to their weaker hydrogen bonding, the concept 
of bifunctionality, by analogy with the catalytic action of some enzymes, has been extensively 
investigated in this area in order to increase their efficiency. In this context, intensive efforts 
have been devoted in studying the behavior of those structures as appropriate catalysts in a wide 
number of valuable organocatalytic processes [77]. Many of these chiral (thio)ureas have been 
already involved in the synthesis of remarkable molecules, such as (+)-esermethole [78], (+)-
harmicine [79], ()-CP-99,994 [80], (+)-yohimbine [81], (R)-()-calycotomine [82], (S)-()-
salsolidine [82], (S)-()-carnegine [82], and ()-epibatidine [83] (Fig XII.8). 
 
Figure XII.7 (Thio)ureas as organocatalysts in natural product synthesis. 
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Figure XII.8 Significant total syntheses involving (thio)urea catalysts. 
 
An elegant 19-steps synthesis of ()-nakadomarin A has been reported by Dixon and co-
workers (Scheme XII.7) [84]. It is a marine hexacyclic alkaloid which exhibits impressive 
biological activities [85], and a challenging complex structure for its total synthesis. A key step 
in this synthetic route is the diastereoselective organocatalyzed Michael addition between β-keto 
ester 12 and nitroalkene 11. For high diastereoselectivity (dr 18:1:0:0) and short reaction time of 
this reaction, bifunctional urea D was required affording intermediate 13 as a single 
diastereomer in 81% yield after isolation. 
N
O
N
H
( )-nakadomarin A
N
O
N
H
N
O
NBoc
OO
OBoc
H2N ( )4
O CH2
alkyne RCM/syn-selective reduction
alkene
RCM
furan/
N-acyliminium
cyclization
OO
N
O
N
OO
O
NO2
nitro-Mannich/
lactamization
diastereoselective
organocatalytic
Michael addition
(cat. D)
O2N
MeO2C
O
N
O
O
O2N
O
N
O
O
MeO
O
+
11
12 13  
Scheme XII.7 Retrosynthetic analysis of ()-nakadomarin A. 
 
Another example of the use of thiourea catalysts in total synthesis was reported by You and co-
workers, where they obtained ()-mesembrine by mean of an organocatalyzed aza-Michael 
addition process (Scheme XII.8) [86]. The crucial step in this route is based on a previous study 
about desymmetrization of cyclohexadienones performed by the same research group [87]. In 
this occasion, the difficult task of controlling the sterically congested chiral arylated quaternary 
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carbon center was reached by the use of bifunctional thiourea E, which facilitated the 
desymmetrization process [88] with high yield and enantioselectivity (91%, 97% ee). 
 
Scheme XII.8 Enantioselective synthesis of ()-mesembrine via desymmetrization of 
cyclohexadienones.  
 
XII.4. Cinchona Alkaloids in Total Synthesis 
Cinchona alkaloids, natural products extracted from Cinchona officinalis, have been extensively 
utilized in medicine as well as chiral ligands in metal catalysis [89]. Moreover, in the last 
decade these compounds have become powerful organocatalysts (Fig XII.9), used as Lewis or 
Brønsted base, and also acting as bifunctional catalysts in numerous examples [90]. Significant 
outcomes have been reached in this field, such as the total synthesis of pregabalin [91], (S)-
baclofen [92], (+)-biotin [93], SNAP-7941 [94], ()-mycestericin E [95], (+)-calanolide A [96], 
(+)-inophyllum B [96], DPP-4 inhibitor [97], mazacidin A and C [98], (+)-fostriecin and (+)-
phoslactomycin B [99] (Fig XII.10). 
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Figure XII.9 Efficient cinchona alkaloids as organocatalysts. 
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Figure XII.10 Target molecules synthetized using cinchona alkaloid organocatalysts. 
 
In the following examples, using cinchona alkaloid catalysis, the key step of the syntheses is an 
asymmetric organocatalytic Henry reaction between a ketone and nitromethane. On the one 
hand, Wang’s group published the total synthesis of (R)-(+)-dioxibrassinin as application of 
their method for the synthesis of chiral 3-hydroxy-2-oxindoles, that are important motifs in a 
variety of natural products and drugs [100] (Scheme XII.9). On the other hand, Gomez Pardo, 
Cossy and co-workers reported the synthesis of SSR 2415686 [101], an active drug in the 
treatment of schizophrenia and irritable bowel syndrome (Scheme XII.9). The construction of 
stereogenic quaternary centers is still an active and challenging task in organic chemistry [102]. 
In both strategies, ketones, as less explored substrates in organocatalytic Henry reaction [103], 
were used allowing the achievement of the required chiral quaternary centers with excellent 
enantioselectivities. 
 
Scheme XII.9 Total syntheses of (R)-(+)-dioxibrassinin and SSR 241586 via organocatalyzed 
Henry reactions. 
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XII.5. Phase Transfer Catalysis in Target Molecule Synthesis 
Although the term phase transfer catalysis was introduced in 1971 by Starks [104], this field 
has received especial attention in the last decades. The use of chiral ammonium salts as catalysts 
(Fig XII.11) have been recognized as an effective tool for organic synthesis and many efforts 
have been spent in both industrial and academic sectors, making possible to develop numerous 
highly enantioselective processes [105]. The applicability of PTC has been well demonstrated 
by the asymmetric synthesis of valuable active targets, such as (+)-cylindricine C [106], (+)-
nemonapride [106,107], BIRT-377 [108], (+)- and ()-methyl dihydrojasmonate [109], 
levobupivacaine [110], and ragaglitazar [111] (Fig XII.12). 
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Figure XII.11 Model phase transfer catalyst structures. 
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Figure XII.12 Appealing compounds synthesized by PTC.  
 
The highly enantioselective syntheses of kurasoin A and B reported by Andrus and co-workers 
are illustrative examples of phase transfer catalysis utility. These compounds are protein 
farnesyltransferase (PFTase) inhibitors and were isolated for the first time from the fermentation 
broth of the soil fungus, Paecilomyces sp. [112], and due to their potential anti-cancer properties 
[113], a few groups have invested efforts in the development of new asymmetric total syntheses 
[114]. Andrus’s research group firstly synthesized kurasoin A in seven-steps (24% overall yield) 
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through a phase-transfer catalyzed benzylation reaction to afford the central core of this PFTase 
inhibitor [115]. Later, the authors also applied a similar alkylation methodology to synthesize 
kurasoin B in nine-steps strategy (34% overall yield) (Scheme XII.10) [116]. 
 
Scheme XII.10 Synthesis of kurasoin A and B by means of PTC. 
 
XII.6 Industrial Applications of Organocatalysis  
In the last four decades, the application of asymmetric catalysis in the industry has registered an 
increasing tendency, due to the importance of synthesizing chiral drugs in the pharmaceutical 
sector [117]. Despite its short history, few organocatalytic methodologies have also been 
successfully extrapolated to industrial applications. Nowadays, intensive efforts are invested 
increasingly in this direction, in order to scale-up organocatalytic procedures [118]. In this case, 
handling high amounts of catalyst could be easier and less toxic, since organocatalysts present 
some advantages respect to transition metal catalysts, such as their stability or recovery, and 
consequently becoming an attractive alternative and a suitable solution in the industrial sector. 
In this section, we briefly show to the reader some relevant industrial organocatalytic processes.  
 
XII.6.1 Aminocatalysis at Industrial Sector 
Most probably, the first and more significant industrial example of an asymmetric 
organocatalyzed process is the well-known Hajos-Parrish-Eder-Sauer-Wiechert reaction [119], 
independently discovered by two research groups in 1971 (Scheme XII.11) [120]. These two 
groups belonging to Schering and Hoffmann-La Roche industrial companies implemented this 
reaction since the early 1970s to manufacture steroids on multi-kilogram scales.  
 
Scheme XII.11 L-Proline catalyzed Hajos-Parrish-Eder-Sauer-Wiechert annulation reaction. 
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This intramolecular aldol reaction has attracted attention from the beginning, for example due to 
the easy access to steroid precursors octahydronaphthalenedione 14 and tetrahydroindanone 15, 
starting from readily available raw materials, and using commercially available L-proline 
catalyst (Fig XII.13) [121].  
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Figure XII.13 Relevant industrial commercialized steroids. 
 
XII.6.2 Thiourea Catalysis at Industrial Scale 
Another significant example utilized by commercially purpose is an asymmetric organocatalytic 
Strecker reaction [122], the most classical approach for the enantioselective preparation of α-
amino acids. In this context, the methodology developed by Jacobsen and co-workers has been 
employed by Rhodia ChiRex for the large-scale synthesis of chiral amino nitriles 16 as useful 
building blocks for its further transformation in natural and unnatural amino acids (Scheme 
XII.12) [123]. The high efficiency of this process is demonstrated by the small amount of 
catalyst (4 mol%) necessary to provide final aminonitriles 16 in high yield and 
enantioselectivity. 
 
Scheme XII.12 Organocatalyzed synthesis of α-amino acids. 
 
XII.6.3 Cinchona Alkaloids at Industrial Level 
As above shown in part XII.4 cinchona alkaloids have been used in several desymmetrization 
processes. In this field, Yue and co-workers have disclosed the stereoselective synthesis of a 
CCR3 antagonist, with potential activity in the prevention of inflammation in asthma and 
allergic rhinitis, in 20-kg pilot-plant manufacture [124]. The authors designed its synthesis from 
fragments 17-19, through a reductive amination between fragment 17 and 18, and urea 
16 
 
formation with fragment 19. The synthetic route for preparation of the key fragment 17 starts 
from quinine-mediated opening of meso-hexahydrophthalic anhydride (20) with EtOH and 
involves seven steps with a 44% overall yield (Scheme XII.13). 
 
 Scheme XII.13 Retrosynthetic analysis of CCR3 antagonist, and synthesis of 17 through a 
desymmetrization reaction. 
 
A desymmetrization step was also envisioned by a research group in Bayer AG to synthesize a 
new antifungal agent BAY 10-888 in multikilogram quantities in a pilot plant [125]. After 
screening different alcohols for the desymmetrization of the anhydride 21, trans-cinnamyl 
alcohol (22) in the presence of stoichiometric amounts of quinine B, provided the best results 
suitable for carrying out the process on a pilot plant scale (Scheme XII.14). 
 
Scheme XII.14 Synthesis of BAY 10-888 through an organocatalytic desymmetrization 
reaction. 
 
XII.6.4 Phase-transfer Catalysis in the Industry 
Maybe one of the most employed organocatalysts at industrial scale are phase transfer catalysts. 
The first phase transfer catalyzed reaction carried out in the industry was developed by Merck 
Company in the mid-1980s [126]. The pioneering explored methodology was the methylation 
reaction of a cyclic ketone 23 in the presence of chiral ammonium salt G to create a chiral 
quaternary center. This process was developed with the objective of synthesizing (+)-
indacrinone (MERCK-0197), a chiral indanone with diuretics properties and commercialized as 
uricosuric drug. The potential of this procedure is also reflected in economic aspects of the 
17 
 
production, since the catalytic process resulted less expensive than the obtainment of the active 
isomer by resolution from the corresponding racemate [126c] (Scheme XII.15). 
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Scheme XII.15 Enantioselective synthesis of (+)-indacrinone. 
 
XII.7 Conclusions 
In this work motivating applications of organocatalysis in the synthesis of relevant biological 
active compounds are presented. The most common organocatalytic approaches, such as 
aminocatalysis, hydrogen bond catalysis, cinchona alkaloids catalysts and phase transfer 
catalysis have been covered. We hope to give to the reader a general overview about the great 
utility of organocatalysis in total synthesis as well as at an industrial level. The examples 
highlighted here show that this kind of catalysis has become a powerful tool in the field of 
asymmetric oriented synthesis, being complementary to transition metal catalysis as well as 
enzymes. However, in spite of all these examples, organocatalysis is still in its infancy and there 
is still a long way to go. Although the role of the organocatalysts is still unclear in some cases, 
many efforts are focused in understanding the mechanism of the processes, which will allow 
overcoming several drawbacks like the need of high catalyst loadings and long reaction times. 
As a result, in the next future, we will assist to the development of new more complex examples 
of remarkable syntheses and its scaled-up for commercial applications is also expected. 
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